Arbutus Biopharma (ABUS) News Today → There’s only one solution to the impending energy catastrophe… (From DTI) (Ad) Free ABUS Stock Alerts $3.01 -0.05 (-1.63%) (As of 06/18/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 18 at 2:50 AM | americanbankingnews.comArbutus Biopharma Co. (NASDAQ:ABUS) Short Interest UpdateJune 13, 2024 | marketbeat.comFourWorld Capital Management LLC Sells 251,056 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS)FourWorld Capital Management LLC reduced its position in shares of Arbutus Biopharma Co. (NASDAQ:ABUS - Free Report) by 18.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,090,851 shares of the biopharmaceutical company's stock afteJune 6, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Trading Down 3%Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 3%June 6, 2024 | globenewswire.comTreatment with Arbutus' Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg LevelsJune 6, 2024 | marketbeat.comArbutus Biopharma's (ABUS) Buy Rating Reiterated at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $5.00 target price on shares of Arbutus Biopharma in a research note on Thursday.June 5, 2024 | marketbeat.comArbutus Biopharma's (ABUS) Buy Rating Reiterated at Chardan CapitalChardan Capital reiterated a "buy" rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a research note on Wednesday.June 5, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Stock Price Up 5.7%Arbutus Biopharma (NASDAQ:ABUS) Trading Up 5.7%June 5, 2024 | globenewswire.comArbutus' Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional CureJune 4, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Hits New 1-Year High at $3.44Arbutus Biopharma (NASDAQ:ABUS) Sets New 52-Week High at $3.44June 3, 2024 | globenewswire.comArbutus Distributors Ltd. News ReleaseJune 2, 2024 | marketbeat.comArbutus Biopharma Co. (NASDAQ:ABUS) Sees Large Decline in Short InterestArbutus Biopharma Co. (NASDAQ:ABUS - Get Free Report) was the recipient of a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 5,340,000 shares, a drop of 8.1% from the April 30th total of 5,810,000 shares. Based on an average daily volume of 1,150,000 shares, the days-to-cover ratio is presently 4.6 days.May 31, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Stock Price Passes Above 200 Day Moving Average of $2.57Arbutus Biopharma (NASDAQ:ABUS) Share Price Passes Above 200 Day Moving Average of $2.57May 29, 2024 | globenewswire.comArbutus to Participate in Jefferies Global Healthcare ConferenceMay 23, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Shares Down 4.7% Arbutus Biopharma (NASDAQ:ABUS) Stock Price Down 4.7%May 22, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Reaches New 52-Week High at $3.29Arbutus Biopharma (NASDAQ:ABUS) Reaches New 12-Month High at $3.29May 22, 2024 | globenewswire.comArbutus to Present Imdusiran Data at EASL Congress 2024May 21, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Trading Up 3.6%Arbutus Biopharma (NASDAQ:ABUS) Trading Up 3.6%May 17, 2024 | morningstar.comArbutus Biopharma Corp ABUSMay 17, 2024 | bizjournals.comMike Sofia, who discovered cure for hepatitis C, set to retire from Arbutus BiopharmaMay 17, 2024 | finance.yahoo.comArbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B ProgramMay 17, 2024 | finance.yahoo.comUpdate: Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B ProgramMay 17, 2024 | businesswire.comWhitefort Capital Publishes Open Letter to Arbutus Biopharma Shareholders Outlining Paths to Maximize ValueMay 10, 2024 | msn.comArbutus Biopharma to Engage Investors at Upcoming New York ConferencesMay 7, 2024 | globenewswire.comArbutus to Participate in Two Upcoming Investor ConferencesMay 3, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Arbutus Biopharma (ABUS), Neurocrine (NBIX) and Bausch Health Companies (BHC)May 3, 2024 | finance.yahoo.comArbutus Biopharma Corp (ABUS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 3, 2024 | finance.yahoo.comArbutus Biopharma First Quarter 2024 Earnings: EPS Beats Expectations, Revenues LagMay 3, 2024 | finance.yahoo.comArbutus Biopharma Corporation (NASDAQ:ABUS) Q1 2024 Earnings Call TranscriptMay 3, 2024 | marketbeat.comArbutus Biopharma's (ABUS) Buy Rating Reaffirmed at Chardan CapitalChardan Capital reissued a "buy" rating and issued a $4.00 price target on shares of Arbutus Biopharma in a research note on Friday.May 3, 2024 | msn.comArbutus Biopharma Makes Headway in Hepatitis B Treatment and Defends Intellectual Property Amidst Q1 2024 Financial ReleaseMay 2, 2024 | finance.yahoo.comArbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial ReviewMay 2, 2024 | investorplace.comABUS Stock Earnings: Arbutus Biopharma Beats EPS, Misses Revenue for Q1 2024May 2, 2024 | washingtonpost.comArbutus: Q1 Earnings SnapshotMay 2, 2024 | globenewswire.comArbutus Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 2, 2024 | globenewswire.comArbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024May 1, 2024 | markets.businessinsider.comArbutus Biopharma earnings: here's what to expectMay 1, 2024 | msn.comArbutus Biopharma Q1 2024 Earnings PreviewApril 30, 2024 | money.usnews.comArbutus Biopharma CorpApril 21, 2024 | msn.comArbutus Biopharma Sets Date for Q1 2024 Financial ResultsApril 18, 2024 | globenewswire.comArbutus to Report First Quarter 2024 Financial Results and Provide Corporate UpdateApril 10, 2024 | seekingalpha.comArbutus Biopharma: The Markman Win Is A Good Milestone But Uncertainty RemainsApril 4, 2024 | msn.comArbutus Vs. Moderna Patent Dispute Over Covid-19 Vaccine Gets Response From JudgeApril 4, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Sees Unusually-High Trading VolumeArbutus Biopharma (NASDAQ:ABUS) Sees Large Volume IncreaseApril 4, 2024 | markets.businessinsider.comArbutus Biopharma Reports Claim Construction Ruling In Patent Infringement Lawsuit Against ModernaApril 4, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Earns "Market Outperform" Rating from JMP SecuritiesJMP Securities reiterated a "market outperform" rating and issued a $4.00 price objective on shares of Arbutus Biopharma in a research note on Thursday.April 4, 2024 | globenewswire.comArbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against ModernaApril 3, 2024 | marketbeat.comArbutus Biopharma (NASDAQ:ABUS) Hits New 52-Week High at $3.25Arbutus Biopharma (NASDAQ:ABUS) Reaches New 52-Week High at $3.25April 3, 2024 | seekingalpha.comArbutus Biopharma jumps after claim construction order in patent fight with ModernaApril 3, 2024 | marketbeat.comTrading was temporarily halted for "ABUS" at 12:04 PM with a stated reason of "LULD pause." Trading set to resume at 12:04 PM. April 1, 2024 | finance.yahoo.comIs Arbutus Biopharma (NASDAQ:ABUS) In A Good Position To Deliver On Growth Plans? Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Options expert shares his top option strategy for free (Ad)A 35 year old man from central Florida has stumbled on one of the best strategies we’ve seen in a long time. For the last 30 months his “Friday to Monday” trading strategy has maintained a 71% win rate on more than 350 trades. That includes multiple big time winners like 82% from Adobe… 77% from Palo Alto… But also a barrage of smaller winners like 20% from AMC… Each of which were opened on a Friday afternoon and closed the very next Monday morning. As you’ll see in his brand new video, this strange strategy has given him the ability to capture big time market moves over the weekend. Check it out, simply follow this link here. ABUS Media Mentions By Week ABUS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ABUS News Sentiment▼1.610.73▲Average Medical News Sentiment ABUS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ABUS Articles This Week▼32▲ABUS Articles Average Week Get Arbutus Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ABUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: KALV News ALT News KMDA News RDHL News GPCR News INDV News BHC News DCPH News JANX News AMRX News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ABUS) was last updated on 6/19/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | SponsoredHistoric NVIDIA partnership could send this tiny AI stock soaring...After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's...Behind the Markets | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredElon Musk: THIS will be bigger than TeslaIf you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you ...Paradigm Press | SponsoredAI Hell Will Break Loose [June 30, 2024] …On June 30, 2024, AI will reach a critical tipping point… Whatever you do, make sure you prepare before Ju...Banyan Hill Publishing | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arbutus Biopharma Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arbutus Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
